Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Icahn School of Medicine at Mount Sinai | OTHER |
| University of South Florida | OTHER |
| Shire | INDUSTRY |
| New York University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this pilot study is to obtain preliminary information on the tolerability and efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette Disorder (TD, also called Tourette syndrome).
Guanfacine is commonly used for the treatment of tics in children with Tourette Disorder, but neither the immediate release compound nor the new extended release formulation have been evaluated for tics as a primary outcome. This pilot study is not designed to demonstrate efficacy of extended release guanfacine in the treatment of tics in children with TD. Rather, the goal of this trial is to determine whether extended release guanfacine warrants further study in a large scale trial. Immediate-release guanfacine is frequently used in children with TD, but dosing, time to effect and adverse effects with the new extended release guanfacine are unknown. The use of placebo in this trial reduces bias in the measurement of outcomes because it ensures blindness in the parent and clinician ratings.
This is a three-site, investigator-initiated, randomized, double-blind, placebo-controlled, parallel-group study. Subjects who show a positive response to extended release guanfacine in the 8-week double-blind phase will continue on the the drug in an 8-week extension phase. Subjects who are randomly assigned to placebo and do not show improvement will be offered 8-weeks of open-label treatment with Intuniv.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Inactive placebo | Placebo Comparator |
| |
| Extended-release Guanfacine | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| placebo | Drug | Administered up to 8 weeks. |
| |
| extended-release guanfacine (Intuniv) |
| Measure | Description | Time Frame |
|---|---|---|
| Yale Global Tic Severity Scale (YGTSS) | The YGTSS is a clinician-rated scale that begins with a systematic inquiry of tic symptoms in the preceding week. Current motor and phonic tics are rated separately according to number, frequency, intensity, complexity, and interference, each rated on 0 to 5 scale with higher scores indicating greater severity/worse outcome (Leckman et al. 1989). The YGTSS yields a total motor score (0-25), a total phonic score (0-25), a total tic score (sum of total motor and total phonic scores; 0-50), and an impairment score (0-50). Higher scores indicate greater severity/worse outcome. | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lawrence D Scahill, MSN, PhD | Emory University | Study Director |
| Barbara J Coffey, MD, MS | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Tanya Murphy, MD, MS | University of South Florida | Principal Investigator |
| Thomas Fernandez, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale Child Study Center | New Haven | Connecticut | 06510 | United States | ||
| University of South Florida |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Inactive Placebo | placebo: Administered up to 8 weeks |
| FG001 | Extended-release Guanfacine | extended-release guanfacine (Intuniv): 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Inactive Placebo | placebo: Administered up to 8 weeks |
| BG001 | Extended-release Guanfacine | extended-release guanfacine (Intuniv): 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Yale Global Tic Severity Scale (YGTSS) | The YGTSS is a clinician-rated scale that begins with a systematic inquiry of tic symptoms in the preceding week. Current motor and phonic tics are rated separately according to number, frequency, intensity, complexity, and interference, each rated on 0 to 5 scale with higher scores indicating greater severity/worse outcome (Leckman et al. 1989). The YGTSS yields a total motor score (0-25), a total phonic score (0-25), a total tic score (sum of total motor and total phonic scores; 0-50), and an impairment score (0-50). Higher scores indicate greater severity/worse outcome. | Posted | Mean | Standard Deviation | units on a scale | 8 weeks |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Inactive Placebo | placebo: Administered up to 8 weeks | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| depressed mood | Psychiatric disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fatigue/tiredness | General disorders | Systematic Assessment |
We are limited by the small size of this subgroup to determine whether children with comorbid CTD and ADHD might have a significant response to extended-release guanfacine, both with regard to tics and ADHD symptoms.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Tanya K. Murphy, MD, MS | University of South Florida | 813-974-2201 | tmurphy@health.usf.edu |
Not provided
| ID | Term |
|---|---|
| D005879 | Tourette Syndrome |
| D020323 | Tics |
| ID | Term |
|---|---|
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016316 | Guanfacine |
| ID | Term |
|---|---|
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D010648 | Phenylacetates |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| Drug |
1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks. |
|
|
| Tampa |
| Florida |
| 33612 |
| United States |
| Mount Sinai School of Medicine | New York | New York | 10029 | United States |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Tanner stage | The Tanner scale categorizes physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, genitals, testicular volume and development of pubic hair in children, adolescents, and adults. There is insufficient space given in this form to list all of the measurements here. In brief, Stage 1: no pubic hair; Stage 2: initial growth of pubic hair, breasts, nipples, scrotum, testes; Stage 3: additional growth of all mentioned in Stage 2. | Count of Participants | Participants |
|
| Yale Global Tic Severity Scale (YGTSS) | The YGTSS is a clinician-rated scale that begins with a systematic inquiry of tic symptoms in the preceding week. Current motor and phonic tics are rated separately according to number, frequency, intensity, complexity, and interference, each rated on 0 to 5 scale with higher scores indicating greater severity/worse outcome (Leckman et al. 1989). The YGTSS yields a total motor score (0-25), a total phonic score (0-25), a total tic score (sum of total motor and total phonic scores; 0-50), and an impairment score (0-50). Higher scores indicate greater severity/worse outcome. | Mean | Standard Deviation | units on a scale |
|
| Clinical Global Impressions (CGI) | Count of Participants | Participants |
|
| Tic Symptom Self-Report (TSSR) | The TSSR (Cohen and Leckman 1984) was completed by a parent or caretaker. It includes 20 motor and 20 phonic tics, each rated 0 to 3. The motor and phonic scores are summed to create a total score. The total score for Tic Symptom Self-Report ranged from 0-120. Higher scores means greater severity/worse outcome. It has been shown to be sensitive to treatment effects (Scahill et al. 2003). | Mean | Standard Deviation | units on a scale |
|
| Premonitory Urge for Tics Scale (PUTS) | The PUTS (Woods et al. 2005) is a 10-item self-report measure of premonitory urges in individuals with tics. Individual item scores (1-4) are summed, yielding a total score (10-40) reflecting the presence and frequency of pre-tic (i.e., premonitory) urges along with relief that may be experienced after tics have been completed. Higher scores means higher frequency of premonitory urges. | Mean | Standard Deviation | units on a scale |
|
| Attention-Deficit/Hyperactivity Disorder Rating Scale (parent) | The ADHD Rating Scale (Reid et al. 1998) is an 18-item, DSM-IV referenced measure rated by a parent or caretaker in this study. The sum of nine inattention items and nine hyperactivity/impulsiveness items (each rated on a 0-3 scale) are included in the total score. The total score for the Attention-Deficit/Hyperactivity Disorder Rating Scale (parent) ranged from 0 to 54. A higher score means greater severity of ADHD symptoms. | Mean | Standard Deviation | units on a scale |
|
| Disruptive Behavior Rating Scale (DBRS) | The DBRS (Barkley and Murphy 2006) is an 8-item measure of oppositional defiant disorder rated by the parent or caretaker, with each item rated on a 0 to 3 scale. The total score is the sum of all 8 item scores. The total score for the Disruptive Behavior Rating Scale (DBRS) ranged from 0 to 24. Higher scores means greater severity of disruptive behaviors. Scores of 12 and higher are considered clinically significant. | Mean | Standard Deviation | units on a scale |
|
| Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | The CY-BOCS (Scahill et al. 1997) is a 10-item, semistructured interview administered by the independent evaluator and is designed to rate the severity of obsessive-compulsive disorder. Scores range from 0 to 40 with higher scores indicating greater severity. | Mean | Standard Deviation | units on a scale |
|
| Rage Outbursts and Anger Rating Scale (ROARS) | The ROARS (Budman et al. 2008) is a 3-item, clinician-rated scale designed to quantify the severity of explosive outbursts in the past week, administered by an independent evaluator. The items are rated from 0 to 3 on frequency, intensity, and duration and then added together for a total score. The total score for the Rage Outbursts and Anger Rating Scale (ROARS) ranged from 0 to 9. Higher scores indicates greater severity. | Mean | Standard Deviation | units on a scale |
|
extended-release guanfacine (Intuniv): 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks. |
|
|
| 18 |
| 0 |
| 18 |
| 4 |
| 18 |
| EG001 | Extended-release Guanfacine | extended-release guanfacine (Intuniv): 1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks | 0 | 16 | 1 | 16 | 14 | 16 |
| Drowsiness | General disorders | Systematic Assessment |
|
| Dry mouth | General disorders | Systematic Assessment |
|
| Headache | General disorders | Systematic Assessment |
|
| Irritability | Social circumstances | Systematic Assessment |
|
| Stomach ache | Gastrointestinal disorders | Systematic Assessment |
|
| Decreased appetite | General disorders | Systematic Assessment |
|
| Depressed mood | Psychiatric disorders | Systematic Assessment |
|
| Dizziness | General disorders | Systematic Assessment |
|
| Emotional/tearful | General disorders | Systematic Assessment |
|
| Daydreaming | General disorders | Systematic Assessment |
|
| Trouble falling asleep | General disorders | Systematic Assessment |
|
| Hypotension | Cardiac disorders | Systematic Assessment |
|
| Skin rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Other vision problems | Eye disorders | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | Systematic Assessment |
|
| Mid-sleep awakening | General disorders | Systematic Assessment |
|
| Increased energy | General disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Increased appetite | General disorders | Systematic Assessment |
|
Not provided
Not provided
| D013981 | Tic Disorders |
| D009069 | Movement Disorders |
| D020271 | Heredodegenerative Disorders, Nervous System |
| D019636 | Neurodegenerative Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D020820 | Dyskinesias |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000146 |
| Acids, Carbocyclic |
| D002264 | Carboxylic Acids |